579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle
Journal for ImmunoTherapy of Cancer（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined